Union Korea Pharm

Union Korea Pharm is a South Korean pharmaceutical company focused on the research, development, manufacture, and commercialization of prescription medicines. The company markets a broad portfolio of established products spanning anti-inflammatory analgesics, brain metabolism enhancers, skeletal muscle relaxants, urinary-system drugs, antihistamines, circulatory-system medicines, antitussive/expectorants, antibiotics, and injectables. It operates manufacturing facilities in Wonju and has historically positioned itself as a domestic branded-generic and specialty pharmaceutical manufacturer rather than a venture-stage biotech innovator. As of 2025-2026, the company has faced severe financial distress, entered court-supervised rehabilitation, and remained subject to trading and listing-related actions, but it continues to exist as an operating pharmaceutical business.